Jeremy Middleton is an accomplished biopharmaceutical executive with over 30 years of experience and has held senior leadership roles in corporate development, strategic planning and operations at both large and entrepreneurial companies. He previously served as Vice President of Corporate Development for Elusys Therapeutics, which focused on monoclonal antibody-based therapeutics to treat infectious diseases. After joining Elusys as a clinical-stage company, he led efforts to develop and win FDA, EU, UK and Health Canada approval for Anthim, a medical countermeasure against anthrax toxin which has been procured by the US government for the US Strategic National Stockpile. Prior to that he served in senior executive roles leading commercial development at rapid-growth specialty companies Valera Pharmaceuticals (developing hydrogel polymer implant technology) and Neose Technologies (which focused on protein therapeutics, including long-acting G-CSF). Before joining Neose, he held leadership positions in immunology and oncology at BASF Pharma and Abbott Laboratories, including serving as Global Product Director of Humira and spearheading the strategic planning and business development efforts which precipitated the sale of BASF Pharma. Earlier in his career, Mr. Middleton held management positions of increasing responsibility at Boots Pharmaceuticals in Europe, Australia, Southeast Asia and the US, where he led numerous initiatives to reengineer pharmaceutical manufacturing facilities and operations in major markets. He has extensive experience in building and leading multifunctional teams and an impressive track record of driving growth for brands such as Synthroid, Vicodin, Vicoprofen, Dilaudid, and Vantas among others. He has been a key contributor to successful exits for several small and mid-sized biopharma companies.
Mr. Middleton has deep expertise in managing public-private partnerships, raising capital and securing non-dilutive funding through US federal (NIH, BARDA, DOD) and foreign (Health Canada) government agencies. He has served as a board member on the Alliance for Biosecurity and on the Infrastructure Advisory Committee of the NJ Office of Homeland Security and Preparedness.